Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06524635 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

A Phase 2 study of Atopic Dermatitis and Hidradenitis Suppurativa, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
2
Study locations

NCT06524635: Recruiting Phase 2 study of Atopic Dermatitis and Hidradenitis Suppurativa, sponsored by AbbVie.

NCT06524635 is a Phase 2 study of Atopic Dermatitis and Hidradenitis Suppurativa that is actively recruiting participants, run by AbbVie. The registered enrollment target is 60 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06524635, a Phase 2 study of Atopic Dermatitis and Hidradenitis Suppurativa, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS and AD. This study will consist of 2 sub-studies: Sub-Study 1 moderate to severe hidradenitis suppurativa and Sub-Study 2 moderate to severe atopic dermatitis. Approximate 60 participants will be enrolled in the study at approximately 2 sites in the US. In Sub-Study 1 HS participants will receive subcutaneous (SC) injections of lutikizumab for up to week 15 with a 70-day follow-up period. In Sub-Study 2 AD, participants will receive subcutaneous (SC) injections of lutikizumab for up to week 14 with a 70-day follow-up period. The study duration for Sub-Studies 1 and 2 is expected to last up to 30 weeks. Participants in Sub-Study 1 (HS) who complete Week 16 and showed a therapeutic benefit to lutikizumab, as confirmed by the investigator, will have the option to enter an open-label long-term extension (LTE) to continue to receive lutikizumab for up to an additional 140 weeks, followed by a 70-day follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.

Primary Outcome

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Conditions Studied

Atopic Dermatitis Hidradenitis Suppurativa

Interventions

  • DRUG Lutikizumab

Study Locations (2)

California

  • Physioseq, LLC /ID# 267266 - Sacramento

Michigan

  • University of Michigan Health System - Ann Arbor /ID# 267275 - Ann Arbor

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-08-14
Est. Completion 2027-02
Phase Phase 2
AbbVie

526 total trials

What NCT06524635 shows while recruiting

NCT06524635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Lutikizumab is the first listed.

NCT06524635 reports a single indexed study location in California, Michigan.

Frequently Asked Questions

What is clinical trial NCT06524635 about?

NCT06524635 is a clinical study titled "A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab". Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with mod...

What is the current status of trial NCT06524635?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-08-14. Estimated completion is 2027-02.

What conditions does trial NCT06524635 study?

This clinical trial studies the following conditions: Atopic Dermatitis, Hidradenitis Suppurativa.

What interventions are being tested in trial NCT06524635?

The interventions under investigation include: Lutikizumab (DRUG).

Who is sponsoring clinical trial NCT06524635?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06524635 being conducted?

This trial has 2 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06524635's enrollment target sits among peer trials

60 104th of 150 higher than 47 of 150 other Atopic Dermatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06524635

Source: ClinicalTrials.gov NCT06524635, the US trial registry maintained by the National Library of Medicine. NCT06524635 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.